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Abstract
Although guidelines are available for hereditary hemochromatosis, a high percentage of the recommendations within them
are not shared between the different guidelines. Our main aim is to provide an objective, simple, brief, and practical set of
recommendations about therapeutic aspects of HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous
genotype, based on the published scientific studies and guidelines, in a form that is reasonably comprehensible to patients
and people without medical training. This final version was approved at the Hemochromatosis International meeting on
12th May 2017 in Los Angeles.
Introduction
Although guidelines are available for hereditary
hemochromatosis (HH), a high percentage of the recom-
mendations within them are not shared between the dif-
ferent guidelines [1]. Our main aim is to provide an
objective, simple, brief, and practical set of recommenda-
tions about therapeutic aspects of HFE hemochromatosis
for p.Cys282Tyr (C282Y/C282Y) homozygous genotype,
based on the published scientific studies and guidelines, in
a form that is reasonably comprehensible to patients and
people without medical training.
The final version of these recommendations was
approved at the Hemochromatosis International meeting on
12th May 2017 in Los Angeles.
Whom to treat and when to start
Patients with HFE p.Cys282Tyr (C282Y/C282Y)
homozygous genotype and biochemical evidence of iron
overload, i.e., increased serum ferritin ([ 300 lg/L in male
and postmenopausal female and[ 200 lg/L in pre-
menopausal female) and increased fasting transferrin sat-
uration (C 45%) [2, 3].
Considerations
• A judgement has to be made for each individual patient
taking into account their ferritin level (according to
local reference value), age, gender, and co-morbidities.
• Patients with other genotypes should be referred for
further advice.
• Recent studies observed a beneficial effect of early and
sustained management of patients with iron excess,
even when iron load is mild or moderately elevated
serum ferritin [4, 5].
• Elevated serum ferritin values are very common and the
most frequent causes are not associated with HH, but
with metabolic syndrome inflammation (ferritin is an
acute-phase protein), alcoholism, and liver damage.
Thus, it is critical to investigate rigorously the cause of
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high serum ferritin values. Searching for increased
plasma transferrin saturation is critical for the diagnosis
of HH, since it corresponds to the basic and earliest
biochemical abnormality in this disease.
• Magnetic resonance imaging (MRI), when available,
may be used to quantify iron overload in the liver (or in
other organs).
Treatment
Phlebotomy (venesection therapy) is the standard treatment
for patients with HH having been used for more than
60 years. It is effective in reducing morbidity and mortality
of HH [6].
Iron overload leads to tissue injury mainly through the
production of reactive oxygen species which damage cell
membranes and organelles, ending up with cellular death.
Thus, to start the treatment is important.
Each 500 mL phlebotomy withdraws approximately
250 mg of iron which is subsequently released, in a com-
pensatory process, from overloaded tissues (especially the
liver), ending up, with phlebotomy repetition, to the total
removal of body iron excess.
How to treat
Initial or induction phase
A phlebotomy schedule of the order of 400–500 mL,
considering body weight, weekly or every 2 weeks has
been proposed [2, 7].
The objective in this phase is usually to reach serum
ferritin at 50 lg/L provided that there is no anemia.
Serum ferritin should be checked once a month until the
values reach the upper normal limits, and every 2 weeks
thereafter, until the final goal of serum ferritin is reached
[2, 3, 5].
Considerations
• The volume and frequency of the phlebotomies should
be adapted to the clinical characteristics and (individ-
ual) tolerance of the patient.
• Tolerance: clinical data (general tolerance and blood
pressure); hemoglobin (levels should not decrease
below 11 g/dL) [7].
• Phlebotomies can be performed in a clinic, hospital,
transfusion/blood donor centers or in certain circum-
stances at home (by a nurse under medical supervision).
• Patients should be well hydrated and fed.
Maintenance phase
The maintenance phase follows the induction phase.
The patient with HH needs lifelong follow-up.
One phlebotomy every 1–4 months, depending on the
patient’s iron status [2, 7].
Efficacy: the usual aim is to maintain ferritin levels
around 50 lg/L (without anemia) [2, 3, 5].
Considerations
• The frequency of maintenance phlebotomy varies
among individuals, ranging from one per month to one
per year [3].
• Hemoglobin levels should not be\ 11 g/dL.
• Hemoglobin value, typically, should be assessed pre-
ceding phlebotomy, especially in older patients, who
are more susceptible to anemia and chronic blood
losses.
• Serum ferritin should be checked at every other
phlebotomy (at the same time as hemoglobin), at least
yearly.
• Fasting transferrin saturation should also be checked, at
least once a year.
• In certain countries, a growing number of patients with
uncomplicated hemochromatosis donate blood or qual-
ify as blood donors. Blood removed from therapeutic
phlebotomy may be used at the discretion of the blood
service [8].
When to stop
Patients who have had iron overload should never stop
having their iron status monitored and their treatment
planned in the light of their iron status, general condition,
and age.
Additional considerations
Diet
A healthy varied diet should be eaten, avoiding foods with
iron fortification such as breakfast cereals. Iron and vitamin
C supplementation and high alcohol consumption should
also be avoided [3]. In certain geographical regions
(especially subtropical), HH patients should avoid raw
shellfish and undercooked pork because of the risk of
severe infections.
Dietary restriction should not replace phlebotomy
therapy.
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Chelation therapy
Iron chelation is usually indicated for iron overload related
to chronic anemias that need repeated transfusions. How-
ever, iron chelators are an alternative treatment (or adju-
vant) only used in rare and special cases of HH, when
phlebotomies are medically contraindicated, simply
impossible owing to poor vein conditions, or the efficacy
was not achieved with phlebotomies.
Possible future of HH therapeutics
Hepcidin-based therapies might, in future, become a
potential adjunct treatment to phlebotomy in the induction
phase or a replacement for the phlebotomy maintenance
phase. The possibility of using hepcidin is based on the
diminishing of hepcidin levels in HH patients, which is
responsible for increased serum iron and transferrin satu-
ration, and subsequently to tissue iron overload [9].
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